487 related articles for article (PubMed ID: 8437104)
1. Differential effects of alkylating agents on the multiple muscarinic receptor subtypes linked to activation of phospholipase C by carbachol in rat brain cortical membranes.
Sallés J; Wallace MA; Fain JN
J Pharmacol Exp Ther; 1993 Feb; 264(2):521-9. PubMed ID: 8437104
[TBL] [Abstract][Full Text] [Related]
2. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
3. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.
Norman AB; Eubanks JH; Creese I
J Pharmacol Exp Ther; 1989 Mar; 248(3):1116-22. PubMed ID: 2703964
[TBL] [Abstract][Full Text] [Related]
4. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.
Forray C; el-Fakahany EE
Mol Pharmacol; 1990 Jun; 37(6):893-902. PubMed ID: 2163015
[TBL] [Abstract][Full Text] [Related]
5. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
6. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
Flynn DD; Mash DC
J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
[TBL] [Abstract][Full Text] [Related]
7. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
8. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
9. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
10. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
[TBL] [Abstract][Full Text] [Related]
11. Absence of receptor reserve at hippocampal muscarinic autoreceptors which inhibit stimulus-dependent acetylcholine release.
Vickroy TW; Malphurs WL; Defiebre NC
J Pharmacol Exp Ther; 1993 Dec; 267(3):1198-204. PubMed ID: 8263780
[TBL] [Abstract][Full Text] [Related]
12. Acute and chronic effects of ethanol on receptor-mediated phosphatidylinositol 4,5-bisphosphate breakdown in mouse brain.
Hoffman PL; Moses F; Luthin GR; Tabakoff B
Mol Pharmacol; 1986 Jul; 30(1):13-8. PubMed ID: 3014307
[TBL] [Abstract][Full Text] [Related]
13. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
14. Different agonist-receptor active conformations for rat brain M1 and M2 muscarinic receptors that are separately coupled to two biochemical effector systems.
McKinney M; Anderson D; Vella-Rountree L
Mol Pharmacol; 1989 Jan; 35(1):39-47. PubMed ID: 2536467
[TBL] [Abstract][Full Text] [Related]
15. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
Lee W; Wolfe BB
Mol Pharmacol; 1989 Nov; 36(5):749-57. PubMed ID: 2555673
[TBL] [Abstract][Full Text] [Related]
16. Muscarinic acetylcholine receptor-mediated phosphoinositide turnover in cultured cerebellar granule cells: desensitization by receptor agonists.
Xu J; Chuang DM
J Pharmacol Exp Ther; 1987 Jul; 242(1):238-44. PubMed ID: 3039110
[TBL] [Abstract][Full Text] [Related]
17. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium.
Dunlap J; Brown JH
Mol Pharmacol; 1983 Jul; 24(1):15-22. PubMed ID: 6135150
[TBL] [Abstract][Full Text] [Related]
19. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
Olianas MC; Maullu C; Onali P
Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
[TBL] [Abstract][Full Text] [Related]
20. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.
Nilvebrant L
Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 1():1-45. PubMed ID: 3524114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]